Amedisys (NASDAQ:AMED) Downgraded by StockNews.com

StockNews.com downgraded shares of Amedisys (NASDAQ:AMED) from a buy rating to a hold rating in a research report released on Friday morning.

A number of other brokerages have also commented on AMED. Cantor Fitzgerald reaffirmed a neutral rating and issued a $101.00 price objective on shares of Amedisys in a report on Thursday. Raymond James reissued a market perform rating on shares of Amedisys in a report on Tuesday, March 26th. Finally, Royal Bank of Canada increased their target price on Amedisys from $97.00 to $100.00 and gave the stock an outperform rating in a report on Monday, March 25th. Eight investment analysts have rated the stock with a hold rating and one has assigned a buy rating to the company’s stock. According to MarketBeat.com, Amedisys has an average rating of Hold and a consensus target price of $97.50.

Amedisys Trading Up 0.7 %

Shares of Amedisys stock opened at $91.79 on Friday. Amedisys has a 12-month low of $73.10 and a 12-month high of $96.44. The stock has a market cap of $3.00 billion, a P/E ratio of -143.42, a P/E/G ratio of 4.32 and a beta of 0.86. The company has a quick ratio of 1.05, a current ratio of 1.05 and a debt-to-equity ratio of 0.32. The business’s 50 day moving average is $92.54 and its 200-day moving average is $93.36.

Amedisys (NASDAQ:AMED) last posted its earnings results on Wednesday, April 24th. The health services provider reported $1.03 earnings per share for the quarter, topping analysts’ consensus estimates of $1.02 by $0.01. Amedisys had a positive return on equity of 13.00% and a negative net margin of 0.91%. The business had revenue of $571.41 million for the quarter, compared to analyst estimates of $565.38 million. During the same period in the previous year, the firm earned $1.00 EPS. The firm’s revenue was up 2.7% compared to the same quarter last year. Equities research analysts predict that Amedisys will post 4.58 earnings per share for the current fiscal year.

Institutional Trading of Amedisys

Institutional investors and hedge funds have recently modified their holdings of the business. Banque Cantonale Vaudoise bought a new stake in shares of Amedisys during the 1st quarter worth $60,000. Cetera Trust Company N.A bought a new stake in shares of Amedisys during the 4th quarter worth $215,000. CWM LLC lifted its position in shares of Amedisys by 40.4% during the 4th quarter. CWM LLC now owns 2,629 shares of the health services provider’s stock worth $250,000 after buying an additional 757 shares during the last quarter. Contravisory Investment Management Inc. bought a new stake in shares of Amedisys during the 4th quarter worth $258,000. Finally, Mesirow Institutional Investment Management Inc. lifted its position in shares of Amedisys by 9.9% during the 4th quarter. Mesirow Institutional Investment Management Inc. now owns 2,844 shares of the health services provider’s stock worth $270,000 after buying an additional 257 shares during the last quarter. 94.36% of the stock is currently owned by institutional investors.

Amedisys Company Profile

Amedisys, Inc, together with its subsidiaries, provides healthcare services in the United States. It operates through three segments: Home Health, Hospice, and High Acuity Care. The Home Health segment offers a range of services in the homes of individuals for the recovery of patients from surgery, chronic disability, or terminal illness, as well as prevents avoidable hospital readmissions through its skilled nurses; nursing services, rehabilitation therapists specialized in physical, speech, and occupational therapy; and social workers and aides for assisting its patients.